Tandem and Dexcom Expand Agreement to Include G4™ PLATINUM Sensor

January 8, 2013

Tandem Diabetes Care, Inc. (“Tandem”) announced today that its Development and Commercialization Agreement with Dexcom, Inc., has been expanded to include Dexcom’s newest continuous glucose monitoring system, the Dexcom G4™ PLATINUM. Dexcom announced in October that the G4 PLATINUM was approved by the U.S. Food and Drug Administration (FDA).

“Dexcom’s G4 PLATINUM sensor is the most accurate and easiest to use technology available, and fits well with our product development plans,” said Kim Blickenstaff, President and Chief Executive Officer of Tandem. “Integration of continuous glucose monitoring functionality is a primary focus at Tandem, and something we intend to deliver.”